E ISSN 2791-7851
pdf
Volume: 3 Issue: 2 Year: 2023
The Modal
Real-world Results of Ocrelizumab in the Treatment of Multiple Sclerosis: A Gulf Region Single-center Experience [J Mult Scler Res]
J Mult Scler Res. 2023; 3(1): 9-13 | DOI: 10.4274/jmsr.galenos.2023.2022-12-2

Real-world Results of Ocrelizumab in the Treatment of Multiple Sclerosis: A Gulf Region Single-center Experience

Ali Hassan1, Heba Elhasin1, Noha Soliman1, Miklos Szolics3
1Tawam Hospital, Department of Medicine, Division of Neurology, Al Ain, United Arab Emirates
2United Arab Emirates University, College of Medicine and Health Sciences, Department of Medicine, Al Ain, United Arab Emirates
3Tawam Hospital, Department of Medicine, Division of Neurology, Al Ain, United Arab Emirates and United Arab Emirates University, College of Medicine and Health Sciences, Department of Medicine, Al Ain, United Arab Emirates

INTRODUCTION: This study aimed to describe the real-world effectiveness and tolerability of ocrelizumab treatment at MS Clinic, Tawam Hospital.
METHODS: This retrospective, observational, single-center study analyzed the medical records of patients with multiple sclerosis (MS) receiving the standard dose of ocrelizumab.
RESULTS: After starting ocrelizumab, 3 of the 19 patients included in the study experienced disease progression, 3 showed disability improvement,
and the remaining 13 had stable status. None of the 15 patients with relapsing-remitting MS experienced a relapse. The average expanded disability status scale of all patients dropped from 2.32 to 2.22, when switched to ocrelizumab. After the follow-up period, 16 (84.21%) patients did not have any magnetic resonance imaging activity.
DISCUSSION AND CONCLUSION: As an MS treatment, ocrelizumab is associated with a favorable response in terms of both efficacy and safety in clinical practice
settings. The efficacy and safety demonstrated must be further evaluated to provide real-world evidence for the use of ocrelizumab.

Keywords: Multiple sclerosis, ocrelizumab, Gulf region

Ali Hassan, Heba Elhasin, Noha Soliman, Miklos Szolics. Real-world Results of Ocrelizumab in the Treatment of Multiple Sclerosis: A Gulf Region Single-center Experience. J Mult Scler Res. 2023; 3(1): 9-13

Corresponding Author: Ali Hassan, United Arab Emirates
Manuscript Language: English
LookUs & Online Makale